Wednesday, August 10, 2016 12:36:42 PM
Yes, DDD, they included HE in the things they used expenses for. Now the question is...are they paying expenses to train personnel at German hospitals in prep of initiating HE, or are they actually providing the treatment to HE patients, perhaps even collecting payment from some patients. Remember, patients can self-pay and be reembursed by health funds once the deals are completed, and out-of-country patients would self-pay anyway.
So my own thought is that NWBO may already have a nice cashe of money set aside in an an escrow account, waiting to reveal once all pricing negotiations are over, including negotiations in the US, if and when DCVaxL is approved. The filing that allowed them not to report a financial matter some short time ago may have given them the right to withhold that info so as not to interfere with pricing in the US. Let's face it, if they revealed they had money coming in from HE, they would have to report the amount they were charging, and Europe is likely to get the treatment for less than we would in the US. At least, I've read that's the case with new drugs/treatments....we pay the bulk of the development cost.
This is just my thoughts.
So my own thought is that NWBO may already have a nice cashe of money set aside in an an escrow account, waiting to reveal once all pricing negotiations are over, including negotiations in the US, if and when DCVaxL is approved. The filing that allowed them not to report a financial matter some short time ago may have given them the right to withhold that info so as not to interfere with pricing in the US. Let's face it, if they revealed they had money coming in from HE, they would have to report the amount they were charging, and Europe is likely to get the treatment for less than we would in the US. At least, I've read that's the case with new drugs/treatments....we pay the bulk of the development cost.
This is just my thoughts.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
